These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 11945152)

  • 1. Gastrointestinal safety of selective COX-2 inhibitors.
    Hawkey CJ; Skelly MM
    Curr Pharm Des; 2002; 8(12):1077-89. PubMed ID: 11945152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current perspective on the cardiovascular effects of coxibs.
    Konstam MA; Weir MR
    Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors.
    Peura DA
    Cleve Clin J Med; 2002; 69 Suppl 1():SI31-9. PubMed ID: 12086291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evidence-based evaluation of the gastrointestinal safety of coxibs.
    Bombardier C
    Am J Cardiol; 2002 Mar; 89(6A):3D-9D. PubMed ID: 11909555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.
    Meyer-Kirchrath J; Schrör K
    Curr Med Chem; 2000 Nov; 7(11):1121-9. PubMed ID: 11032962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors.
    Scheiman JM
    Cleve Clin J Med; 2002; 69 Suppl 1():SI40-6. PubMed ID: 12086292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal safety of coxibs and outcomes studies: what's the verdict?
    Laine L
    J Pain Symptom Manage; 2002 Apr; 23(4 Suppl):S5-10; discussion S11-4. PubMed ID: 11992743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects].
    Blain H; Jouzeau JY; Netter P; Jeandel C
    Rev Med Interne; 2000 Nov; 21(11):978-88. PubMed ID: 11109595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs.
    Naesdal J; Wilson I
    Eur J Gastroenterol Hepatol; 2001 Dec; 13(12):1401-6. PubMed ID: 11742186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
    Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A
    Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
    Laine L
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COX-2 inhibitors vs. NSAIDs in gastrointestinal damage and prevention.
    Ballinger A; Smith G
    Expert Opin Pharmacother; 2001 Jan; 2(1):31-40. PubMed ID: 11336566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-inflammatory drugs in the 21st century.
    Rainsford KD
    Subcell Biochem; 2007; 42():3-27. PubMed ID: 17612044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.
    Hawkey CJ; Jackson L; Harper SE; Simon TJ; Mortensen E; Lines CR
    Aliment Pharmacol Ther; 2001 Jan; 15(1):1-9. PubMed ID: 11136272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
    Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract.
    Bjarnason I; Thjodleifsson B
    Rheumatology (Oxford); 1999 May; 38 Suppl 1():24-32. PubMed ID: 10369403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COX-2 inhibitors and the cardiovascular system.
    FitzGerald GA; Cheng Y; Austin S
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S31-6. PubMed ID: 11695249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.